# A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

> **NCT03334084** · PHASE1 · COMPLETED · sponsor: **argenx** · enrollment: 40 (actual)

## Conditions studied

- Bioavailability Study

## Interventions

- **DRUG:** ARGX-113

## Key facts

- **NCT ID:** NCT03334084
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-11
- **Primary completion:** 2018-09-19
- **Final completion:** 2018-09-19
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03334084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03334084, "A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03334084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*